Pliant Therapeutics Inc (STU:9PT)
€ 13.3 0.4 (3.05%) Market Cap: 833.15 Mil Enterprise Value: 487.01 Mil PE Ratio: 0 PB Ratio: 2.23 GF Score: 35/100

Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call Transcript

Feb 05, 2024 / 01:30PM GMT
Release Date Price: €16 (-3.61%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to Pliant Therapeutics' INTEGRIS-PSC Phase 2a Trial 320 milligram. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a call.

(Operator Instructions) Please be advised that today's conference is being recorded. I would like now to turn the conference over to Christopher Keenan, Vice President of Investor Relations. Please go ahead.

Christopher Keenan
Pliant Therapeutics Inc - Vice President - Investor Relations and Corporate Communications

Thank you, Michelle, and good morning, everyone. Thank you for joining us for Pliant's presentation of top-line data from the 320 mg dose group of INTEGRIS-PSC, our Phase 2a clinical trial evaluating bexotegrast, previously known as PLN-74809 in patients with primary sclerosing cholangitis. The press release that we will be referencing today is available under the Investors and Media section of our corporate website. A replay of this event and the slides accompanying this webcast will be available in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot